Literature DB >> 19553868

Update on key previously proposed candidate genes for schizophrenia.

Sibylle G Schwab1, Dieter B Wildenauer.   

Abstract

PURPOSE OF REVIEW: We will give an overview of more recent data concerning previously implicated candidate genes for schizophrenia. This includes functional data when available. Furthermore, studies on copy number repeats and their possible implications in schizophrenia will be described. RECENT
FINDINGS: Within the past year, schizophrenia genetics has focused on a more detailed investigation of previously implicated candidate genes. In addition, investigation of copy number variations has led to the identification of rare structural DNA variants that might play a major role in some cases of schizophrenia.
SUMMARY: There is emerging evidence that some cases of schizophrenia might be due to rare genetic structural variation, though the majority of cases should be due to a cumulative effect of common variations in multiple genes, which in combination with environmental stressors may lead to the development of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19553868     DOI: 10.1097/YCO.0b013e328325a598

Source DB:  PubMed          Journal:  Curr Opin Psychiatry        ISSN: 0951-7367            Impact factor:   4.741


  13 in total

Review 1.  Search for missing schizophrenia genes will require a new developmental neurogenomic perspective.

Authors:  H B Kiran Kumar; Christina Castellani; Sujit Maiti; Richard O'Reilly; Shiva M Singh
Journal:  J Genet       Date:  2013       Impact factor: 1.166

2.  DISC1 regulates primary cilia that display specific dopamine receptors.

Authors:  Aaron Marley; Mark von Zastrow
Journal:  PLoS One       Date:  2010-05-28       Impact factor: 3.240

3.  A sex- and region-specific role of Akt1 in the modulation of methamphetamine-induced hyperlocomotion and striatal neuronal activity: implications in schizophrenia and methamphetamine-induced psychosis.

Authors:  Yi-Wen Chen; Hui-Yun Kao; Ming-Yuan Min; Wen-Sung Lai
Journal:  Schizophr Bull       Date:  2013-03-08       Impact factor: 9.306

Review 4.  Modeling resilience to schizophrenia in genetically modified mice: a novel approach to drug discovery.

Authors:  Andra Mihali; Shreya Subramani; Genevieve Kaunitz; Stephen Rayport; Inna Gaisler-Salomon
Journal:  Expert Rev Neurother       Date:  2012-07       Impact factor: 4.618

5.  Modification and functional inhibition of regulator of G-protein signaling 4 (RGS4) by 4-hydroxy-2-nonenal.

Authors:  C Aaron Monroy; Jonathan A Doorn; David L Roman
Journal:  Chem Res Toxicol       Date:  2013-11-14       Impact factor: 3.739

Review 6.  Dysbindin-containing complexes and their proposed functions in brain: from zero to (too) many in a decade.

Authors:  Cristina A Ghiani; Esteban C Dell'Angelica
Journal:  ASN Neuro       Date:  2011-05-27       Impact factor: 4.146

7.  Distinct phenotypes of new transmembrane-domain neuregulin 1 mutant mice and the rescue effects of valproate on the observed schizophrenia-related cognitive deficits.

Authors:  Ju-Chun Pei; Chih-Min Liu; Wen-Sung Lai
Journal:  Front Behav Neurosci       Date:  2014-04-14       Impact factor: 3.558

8.  Association of the Nicotinic Receptor α7 Subunit Gene (CHRNA7) with Schizophrenia and Visual Backward Masking.

Authors:  George Bakanidze; Maya Roinishvili; Eka Chkonia; Werner Kitzrow; Sarina Richter; Konrad Neumann; Michael H Herzog; Andreas Brand; Imke Puls
Journal:  Front Psychiatry       Date:  2013-10-22       Impact factor: 4.157

9.  Investigation of gene effects and epistatic interactions between Akt1 and neuregulin 1 in the regulation of behavioral phenotypes and social functions in genetic mouse models of schizophrenia.

Authors:  Ching-Hsun Huang; Ju-Chun Pei; Da-Zhong Luo; Ching Chen; Yi-Wen Chen; Wen-Sung Lai
Journal:  Front Behav Neurosci       Date:  2015-01-29       Impact factor: 3.558

10.  Enzyme activity of the PIP4K2A gene product polymorphism that is implicated in schizophrenia.

Authors:  Jonathan H Clarke; Robin F Irvine
Journal:  Psychopharmacology (Berl)       Date:  2013-10-01       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.